Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASH 2020

Latest Videos

View all
2:19
AML: what to look forward to at ASH 2020
Thomas Prebet • 18 Nov 2020
2:46
Significant CLL trial updates to come at ASH 2020
John Gribben • 20 Nov 2020
1:28
Myeloma at ASH 2020: what to expect?
Noopur Raje • 23 Nov 2020
2:04
Upcoming news in the MPN field at ASH 2020
Naveen Pemmaraju • 23 Nov 2020

Latest Videos

View all
2:19
AML: what to look forward to at ASH 2020
Thomas Prebet • 18 Nov 2020
2:46
Significant CLL trial updates to come at ASH 2020
John Gribben • 20 Nov 2020
1:28
Myeloma at ASH 2020: what to expect?
Noopur Raje • 23 Nov 2020
2:04
Upcoming news in the MPN field at ASH 2020
Naveen Pemmaraju • 23 Nov 2020

Multiple Myeloma

View all
1:42
First-in-human trial of an anti-BCMA ADC for R/R myeloma
Meletios Dimopoulos • 5 Dec 2020
2:38
CRB-402 study update: T-cell phenotypes in myeloma
Jesús Berdeja • 11 Dec 2020

Lymphoma

View all
2:24
Blinatumomab consolidation therapy for DLBCL
John DiPersio • 8 Dec 2020
2:26
Pivotal findings at ASH 2020
Constantine Tam • 10 Dec 2020

CLL

View all
2:28
Accelerated venetoclax ramp-up for R/R CLL
Matthew Davids • 5 Dec 2020
8:04
The MURANO study in CLL: 5 years on
John Seymour • 7 Dec 2020

AML

View all
7:32
Current immune checkpoint inhibitor trials in AML/MDS
Amer Zeidan • 7 Dec 2020
2:43
SIERRA: Iomab-B for pre-HSCT AML
Sergio Giralt • 14 Dec 2020

CAR-T

View all
1:28
Myeloma at ASH 2020: what to expect?
Noopur Raje • 23 Nov 2020
0:57
ASH 2020: CAR-T updates to look out for
Tara Gregory • 23 Nov 2020

Transplant

View all
3:25
Measurable M-spike before ASCT associated with shorter survival in AL Amyloidosis
Morie Gertz • 30 Nov 2020
3:34
ASCT eligibility in myeloma patients aged ≥ 75
Morie Gertz • 30 Nov 2020

MDS

View all
2:19
Imetelstat for transfusion-dependent R/R MDS
Uwe Platzbecker • 17 Dec 2020
2:00
NKG2D CAR-T cell therapy in AML/MDS
David Sallman • 10 Dec 2020

MRD

View all
2:09
Using MRD in myeloma clinical practice
Alessandro Gozzetti • 27 Nov 2020
3:19
Discordances between immunofixation vs NGF vs NGS in myeloma
Bruno Paiva • 27 Nov 2020

MPNs

View all
4:34
PV highlights at ASH 2020
Prithviraj Bose • 11 Dec 2020
4:15
Updates in MPNs at ASH 2020
Aaron Gerds • 7 Dec 2020

ALL

View all
4:12
Advancing treatments in leukemia are transforming patient outcomes
Hagop Kantarjian • 30 Nov 2020
3:42
Prior blinatumomab use impacts CD19-CAR T-cell therapy response rates in R/R ALL
Nirali Shah • 25 Nov 2020
The content of VJHemOnc is intended for healthcare professionals